Develops therapies and diagnostics for misfolded protein diseases, such as Alzheimer's and Parkinson's.
Dec 2025Revenue CHF 3.57M/yrExpenses CHF 72.9M/yr
No trendCash runway ≈ 5 months from Dec 2025
Figures by year
When will AC Immune be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was CHF 3.57M and expenses CHF 72.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | CHF 3.57M | CHF 72.9M | −CHF 69.3M |
| Dec 2024 | CHF 27.3M | CHF 79.7M | −CHF 52.4M |
| Dec 2023 | CHF 14.8M | CHF 68.4M | −CHF 53.6M |
| Dec 2022 | CHF 3.94M | CHF 74.8M | −CHF 70.8M |
| Dec 2021 | CHF 0.00 | CHF 79.0M | −CHF 79.0M |
| Dec 2020 | CHF 15.4M | CHF 76.7M | −CHF 61.3M |
| Dec 2019 | CHF 110M | CHF 65.9M | CHF 44.5M |
| Dec 2018 | CHF 6.91M | CHF 56.5M | −CHF 49.5M |
| Dec 2017 | CHF 20.3M | CHF 42.8M | −CHF 22.5M |
| Dec 2016 | CHF 23.2M | CHF 33.7M | −CHF 10.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.